Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy

ALAMEDA, Calif.– Infinimmune, a biotechnology company pioneering antibody discovery and design, today announced the appointment of Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy. In this role, Dr. Slavin will lead the development and execution of the company’s portfolio strategy, supporting the advancement of Infinimmune’s pipeline and long-term growth.

Prior to joining Infinimmune, Dr. Slavin was an Entrepreneur in Residence at Atlas Venture and held senior leadership roles at Kymera Therapeutics, AbbVie, and Boehringer Ingelheim, where he led immunology and inflammation portfolios and advanced multiple programs from target identification through clinical development. He has contributed to the advancement of several therapeutic programs from early discovery through approval, including upadacitinib, risankizumab, and spesolimab. Earlier in his career, Dr. Slavin served as a Group Leader at the Genomics Institute of the Novartis Research Foundation.

“Anthony brings a rare combination of scientific depth, strategic leadership, and proven execution across modalities and therapeutic areas,” said Wyatt McDonnell, CEO and Co-Founder, Infinimmune. “As we continue to scale our platform, his experience advancing programs into the clinic will be instrumental in shaping our next phase of growth.”

“Infinimmune is at the forefront of a new paradigm in antibody discovery, leveraging the human immune system and AI to unlock novel therapeutics,” said Dr. Slavin. “I’m excited to join the team at this pivotal time and help shape a portfolio that fully realizes the potential of the company’s platform.”

Dr. Slavin holds a Ph.D. in Pathology from The University of Melbourne and completed postdoctoral training at Harvard Medical School and Stanford University. He has authored more than XX scientific publications.

About Infinimmune

Infinimmune is a biotechnology company developing next-generation antibody therapeutics by discovering antibodies directly from the human immune system. The company’s Anthrobody^® platform enables the screening of millions of single memory B cells to identify fully human antibodies across hundreds of targets. Combined with the company’s GLIMPSE™ antibody language model, this approach enables the rapid discovery and optimization of antibodies with strong affinity, specificity, and favorable developability characteristics. For more information, visit www.infinimmune.com.

Media Contact
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744